Subscribe To

Price Alert Latest News Economic Calendar News

INAB / IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference

NEW YORK, Feb. 21, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will present a fireside chat at the H.C. Wainwright Cell Therapy Virtual Conference on Tuesday, February 28, 2023 at 1:30 pm ET. Read More

Demo Live Account See Partner Details

Content Topics

In8bio

Present

Wainwright

Cell

Therapy

Virtual

Conference

Stock

INAB

Posted: Feb 21 2023, 07:00

Author Name: GlobeNewsWire

INAB News

By GlobeNewsWire
November 2, 2023

IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta

By Zacks Investment Research
June 5, 2023

IN8bio, Inc. (INAB)'s Technical Outlook is Bright After Key Golden Cross

IN8bio, Inc. (INAB) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, INAB's 50-day

By Zacks Investment Research
May 24, 2023

IN8bio, Inc. (INAB) Is Up 37.87% in One Week: What You Should Know

Does IN8bio, Inc. (INAB) have what it takes to be a top stock pick for momentum investors? Let's find out.

By PennyStocks
May 2, 2023

Stock Market Today: Penny Stocks To Watch Amid Banking Crisis

Penny stocks to watch as bank stocks fall in the stock market today. The post Stock Market Today: Penny Stocks To Watch Amid Banking Crisis appeared f

By InvestorPlace
April 26, 2023

Why Is IN8bio (INAB) Stock Up 9% Today?

IN8bio (NASDAQ: INAB ) stock is rising higher on Wednesday as the company's shares continue their wild swings this week. The strong movement for the s

By Proactive Investors
April 25, 2023

IN8bio stock price falls even as company receives FDA orphan drug status for brain cancer treatment

IN8bio (NASDAQ:INAB), Inc shares slid 16% to $2.51 in early Tuesday trading after the biopharmaceutical company announced that it has received orphan

By InvestorPlace
April 25, 2023

What Is Going on With In8bio (INAB) Stock Today?

In8bio (NASDAQ: INAB ) stock is on the move Tuesday as investors react to a recent rally and additional news from the biotechnology company. First off

By GlobeNewsWire
April 11, 2023

IN8bio to Present New Positive Clinical Data from Phase 1 Trial of INB-100 at EBMT 2023 Annual Meeting

NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innova

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.